Cadila Healthcare shares rise 3% on DCGI nod to Phase III clinical trials of COVID-19 vaccine
In Phase II, the vaccine ZyCoV-D was found to be safe and elicited a strong immunogenic response.04-01-2021
Cadila Healthcare shares rise 3% on DCGI nod to Phase III clinical trials of COVID-19 vaccine
In Phase II, the vaccine ZyCoV-D was found to be safe and elicited a strong immunogenic response.CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed a copy of press release dated January 3, 2021 'Zydus Cadila receives approvals from the DCGI to start Phase III Clinical Trial of ZyCoV-D- fully indigenously developed vaccine'.What sets Zydus Cadila apart among indigenous players in Covid vaccine race
The company says the stability of the vaccine is one of its biggest advantages amid dry runs of mass vaccination programmes being conducted in some statesZydus Cadila receives DCGI nod for NAFLD drug in India
The Drug Controller General of India (DCGI) has approved the new drug application (NDA) for Saroglitazar Mg for the treatment of non-alcoholic fatty liver disease (NAFLD) in India, Zydus Cadila said in a regulatory filing.CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus announces the approval of Saroglitazar Mg for the treatment of Non-Alcoholic Fatty Liver Disease in IndiaZydus Cadila plans to test its COVID-19 vaccine on 30,000 volunteers in late stage trial
Cadila Healthcare said its vaccine was found to be well tolerated and immunogenic in the Phase I/II clinical trials.CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila submits Phase I/II clinical trial data of ZyCoV-D, seeks nod to start Phase III Clinical TrialsCADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Webcast of our Managing Director with group of investorsCADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate